The company has sufficient cash until February2017
Btw final phase 3 results for ZopTec in endometrial cancer will be released by the end of 2016.
From the conference call last August:
'Finally, I’d like to address our current financial position in the recent pressure on our stock price. During the first quarter of this year, we made the decision to raise a significant amount of capital to support us through the next 18 months of the implementation of our strategy.'
The company has TWO products in phase 3:
ZopTec for endometrial cancer with final evaluation by the DSMB on safety and efficacy early October. It has the potential to become the first FDA approved treatment for endometrial cancer.
Macrilen for the diagnosis of Adult Growth Hormone Deficiency. It has the potential to become the golden standard in diagnosing AGHD.
The company also has TWO products which have met their primary endpoint without safety concerns:
ZopTec for ovarian cancer and heavily pretreated prostate cancer.
More:
DSMB-safety/efficacy evaluation-early October
Option 1. DSMB advices to continue the trial
Option 2. DSMB advices for immediate FDA approval based on superior safety and efficacy
Option 3. DSMB advices to end the trial b/c of lack of efficacy
Price estimates:
Option 1. $.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes
1.23=consensus price target of 5 analysts
Option 2. at least $3.5/share or a market cap of 2.5 billion dollar
ZopTec will then be the only FDA approved treatment for endometrial cancer with possible 750 million dollar ANNUAL revenu in the US+Europe (Sinopharm royalties for China, Macau and Hong Kong not included)
Option 3. $.10 based on their latest cash position of $45m and Saizen+Estrogel
More: some other important notes on their pipeline:
1.An oral vaccin partnered with a German company which will pay for the enterie development, pays an upfront fee, milestones and royalties once commercialized
2 ERK-inhibitors, partnered for 12 months (pre-)clinical testing with a German company, with an option for development and commercialization after 12months testing. Upfront fee, milestones and royalties.
